Integra LifeSciences

Integra LifeSciences was founded by Richard Caruso in 1989 after Caruso licensed Integra artificial skin technology from Harvard–MIT and acquired Colla-tec, a subsidiary of Marion Laboratories.{{Cite book|last=Crosby|first=John C.|url=https://play.google.com/books/reader?id=ORWdDwAAQBAJ&pg=GBS.PT140.w.2.0.55_289&hl=en|title=Built to Help Each Other: Mentoring in the Life of Richard Caruso: An Uncommon Man|date=2019-06-13|publisher=Radius Book Group|isbn=978-1-63576-708-7|language=en}} The company became publicly traded under the NASDAQ ticker name IART.

In 1996, Integra artificial skin was approved by the U.S. Food and Drug Administration.{{Cite news|last=Schaffer|first=Amanda|date=2006-05-02|title=Cadaver Skin Fills the Gap in Burn Cases|language=en-US|work=The New York Times|url=https://www.nytimes.com/2006/05/02/health/02skin.html|access-date=2021-10-14|issn=0362-4331}} The artificial skin, manufactured and patented as Integra, is now used on patients with extensive burns. In 1999, the FDA approved Integra LifeSciences’ DuraGen, an absorbable implant used in neurosurgical and spinal procedures.{{Cite web|title=Integra Lifesciences Cleared to Market New Dural Graft Matrix|url=https://www.meddeviceonline.com/doc/integra-lifesciences-cleared-to-market-new-du-0001|access-date=2021-10-14|website=www.meddeviceonline.com}}

In 2001, NMT, a company acquired by Integra in 2002,https://investor.integralife.com/news-releases/news-release-details/integra-lifesciences-acquires-neurosciences-division-nmt-medical {{Bare URL inline|date=August 2024}} received FDA approval for Licox, a brain tissue oxygen and temperature monitor.{{Cite journal|last=Stewart|first=Campbell|title=The New Licox Combined Brain Tissue Oxygen and Brain Temperature Monitor|date=December 1, 2008|url=https://academic.oup.com/neurosurgery/article-abstract/63/6/1159/2558179?redirectedFrom=fulltext|journal=Neurosurgery |volume=63|issue=6|pages=1159–1165|doi=10.1227/01.NEU.0000333265.19131.7C|pmid=19057329|s2cid=33380827|via=Oxford Academic|url-access=subscription}}{{Cite book|last1=Layon|first1=Joseph A.|url=https://books.google.com/books?id=rDS3BAAAQBAJ|title=Textbook of Neurointensive Care|last2=Gabrielli|first2=Andrea|last3=Friedman|first3=William A.|publisher=Springer|year=2013|isbn=978-1-4471-5225-5|pages=135}} Licox is used to treat patients in critical care, including those suffering from traumatic brain injuries.

In 2002, the FDA approved the use of Integra Dermal Regeneration Template for reconstructive surgery of burn scars.{{Cite web|date=2018-11-03|title=FDA approves Integra Omnigraft Dermal Regeneration Matrix to treat diabetic foot ulcers|url=https://www.fda.gov/news-events/press-announcements/fda-approves-integra-omnigraft-dermal-regeneration-matrix-treat-diabetic-foot-ulcers|archive-url=https://web.archive.org/web/20190925021503/https://www.fda.gov/news-events/press-announcements/fda-approves-integra-omnigraft-dermal-regeneration-matrix-treat-diabetic-foot-ulcers|url-status=dead|archive-date=September 25, 2019|access-date=2021-10-14|website=FDA|language=en}} In 2016, IDRT received premarket approval from the FDA for the treatment of diabetic foot ulcers.{{Cite web|title=Premarket Approval (PMA)|url=https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P900033S042|access-date=2021-10-14|website=www.accessdata.fda.gov}}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}

In 2018, Integra LifeSciences was included in Fortune’s list of Fastest Growing Companies.{{Cite web |title=Inside Fortune's 2018 Fastest-Growing Companies List |url=https://fortune.com/100-fastest-growing-companies/2018/visualizations/ |archive-url=https://web.archive.org/web/20200824012004/https://fortune.com/100-fastest-growing-companies/2018/visualizations/ |url-status=dead |archive-date=August 24, 2020 |access-date=2022-03-01 |website=Fortune |language=en }}

In 2023, Integra ranked #59 on Medical Design and Outsourcing’s list of largest medical technology companies in the world.{{Cite web |title=The 2023 Medtech Big 100: The world's largest medical device companies |url=https://www.medicaldesignandoutsourcing.com/2023-medtech-big-100-largest-medical-device-companies/ |access-date=2023-09-03 |website=Medical Design and Outsourcing |language=en-US}}

In 1969, John F. Burke, a surgeon and Harvard Medical School professor, and Ioannis V. Yannas, a mechanical engineering professor of fibers and polymers at MIT, began working on a new form of artificial skin. They created the first commercially reproducible artificial skin, later patented and manufactured as Integra.

Integra is used to treat patients with severe burns. The top layer, made of thin silicone, protects the patient from infection and dehydration, common causes of death after being severely burned. The bottom layer, made of animal tissue, acts as scaffolding where new skin will grow.{{Cite book|url=http://archive.org/details/sim_fda-consumer_2002-06_36_3|title=FDA Consumer 2002-06: Vol 36 Iss 3|date=June 2002|publisher=Superintendent of Documents|language=English}} Compared to traditional skin grafts, the use of Integra reduces pain and scarring.

Integra is also used in plastic surgery, reconstructive surgery, and to treat some forms of cancer and other skin wounds.{{Cite journal|last1=Thinda|first1=Sumeer|last2=Wright|first2=Harry V.|last3=Mawn|first3=Louise A.|date=February 2012|title=Integra Bilayer Matrix Wound Dressing Closure of Large Periorbital Traumatic Wound|url=https://jamanetwork.com/journals/jamaophthalmology/fullarticle/1106568|journal=Arch Ophthalmol|volume=130|issue=2|pages=217–219|doi=10.1001/archopthalmol.2011.1178|pmid=22332215|via=JAMA Network|url-access=subscription}}{{Cite journal|last1=Chang|first1=Daniel K.|last2=Louis|first2=Matthew R.|last3=Gimenez|first3=Alejandro|last4=Reece|first4=Edward M.|date=August 2, 2019|title=The Basics of Integra Dermal Regeneration Template and its Expanding Clinical Applications|journal=Seminars in Plastic Surgery|volume=33|issue=3|pages=185–189|doi=10.1055/s-0039-1693401|pmid=31384234|pmc=6680073}}{{Cite journal|last1=Chalmers|first1=R L|last2=Smock|first2=E|last3=Geh|first3=J L C|date=March 23, 2010|title=Experience of Integra(®) in cancer reconstructive surgery|url=https://pubmed.ncbi.nlm.nih.gov/20335086/|journal= Journal of Plastic, Reconstructive & Aesthetic Surgery|volume=63|issue=12|pages=2081–2090|doi=10.1016/j.bjps.2010.02.025|pmid=20335086|via=National Library of Medicine}}

In October 2014, Integra LifeSciences acquired instrumentation lines from Medtronic for $60 million.{{Cite web|date=October 27, 2014|title=Integra LifeSciences closes MicroFrance, Xomed buy from Medtronic|url=https://www.massdevice.com/integra-lifesciences-closes-microfrance-xomed-buy-medtronic/|access-date=|website=MassDevice|language=en-US}} In January 2014, the company bought Covidien’s Confluent Surgical line of sealants and shields.{{Cite web|date=January 16, 2014|title=Covidien closes $235M divestiture of Confluent to Integra LifeSciences|url=https://www.massdevice.com/covidien-closes-235m-divestiture-confluent-integra-lifesciences/|access-date=2022-01-19|website=MassDevice|language=en-US}}

In July 2015, Integra LifeSciences acquired TEI Biosciences and TEI Medical and began manufacturing their SurgiMend and PriMatrix product lines.{{Cite web|date=2015-07-20|title=Integra LifeSciences Completes Acquisition Of TEI Biosciences, TEI Medical|url=https://www.meddeviceonline.com/doc/integra-lifesciences-completes-acquisition-of-tei-biosciences-tei-medical-0001|access-date=2022-02-22|website=www.meddeviceonline.com}}{{Cite web|title=510(k) Premarket Notification|url=https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K171357|access-date=2022-02-22|website=www.accessdata.fda.gov}} Primatrix, a dermal repair scaffolding product, is used to treat diabetic foot ulcers, burns, and in other procedures.{{Cite journal|last=Karr|first=Jeffrey|title=Retrospective Comparison of Diabetic Foot Ulcer and Venous Stasis Ulcer Healing Outcome Between a Dermal Repair Scaffold (PriMatrix) and a Bilayered Living Cell Therapy (Apligraf)|url=https://www.researchgate.net/publication/49840669|journal=Advances in Skin & Wound Care|year=2011 |volume=24 |issue=3 |pages=119–125 |doi=10.1097/01.ASW.0000395038.28398.88|pmid=21326023 |s2cid=26391378 }}{{Cite journal|last1=Parcells|first1=Alexis Lanteri|last2=Karcich|first2=Jenika|last3=Granick|first3=Mark S.|last4=Marano|first4=Michael A.|date=2014-09-24|title=The Use of Fetal Bovine Dermal Scaffold (PriMatrix) in the Management of Full-Thickness Hand Burns|journal=ePlasty|volume=14|pages=e36|issn=1937-5719|pmc=4182964|pmid=25328569}}

In January 2017, Integra Lifesciences acquired Derma Sciences for $204 million.{{Cite web|last=Hodsden|first=Suzanne|date=2017-01-13|title=Integra LifeSciences Acquirers Derma Sciences for $204M, Expands Regenerative Technology Offerings|url=https://www.meddeviceonline.com/doc/integra-lifesciences-acquirers-derma-sciences-for-m-expands-regenerative-technology-offerings-0001|access-date=2022-02-17|website=www.meddeviceonline.com}} Their TCC-EZ Total Contact Cast, used to treat diabetic foot ulcers, reduces pressure and shortens application time compared to a conventional total contact cast.{{Cite journal|last1=Arnold|first1=Jonathan F.|last2=Marmolejo|first2=Valerie|date=October 2017|title=Outcomes Achieved With Use of a Prefabricated Roll-On Total Contact Cast|url=https://pubmed.ncbi.nlm.nih.gov/28800712/|journal=Foot & Ankle International|volume=38|issue=10|pages=1126–1131|doi=10.1177/1071100717716486|issn=1944-7876|pmid=28800712|s2cid=40470722}}{{Cite journal|last1=Messenger|first1=Grace|last2=Masoetsa|first2=Richard|last3=Hussain|first3=Imtiaz|date=2018-06-07|title=A Narrative Review of the Benefits and Risks of Total Contact Casts in the Management of Diabetic Foot Ulcers|journal=The Journal of the American College of Clinical Wound Specialists|volume=9|issue=1–3|pages=19–23|doi=10.1016/j.jccw.2018.05.002|issn=2213-5103|pmc=6304285|pmid=30591897}}

In October 2017, Integra LifeSciences acquired Johnson & Johnson’s Codman Neurosurgery business for $1.045 billion.{{Cite web|last=Newmarker|first=Chris|date=2017-10-02|title=Integra LifeSciences completes purchase of J&J's Codman Neurosurgery|url=https://www.massdevice.com/integra-completes-codman-buy/|access-date=2022-02-09|website=MassDevice|language=en-US}} The Codman Hakim valve was developed as a new way to treat hydrocephalus.{{Cite journal|last1=Gunderman|first1=Richard|last2=Lopez|first2=Gloria|date=2019-01-17|title=Who was Hakim?|url=https://meddocsonline.org/journal-of-radiology-and-medical-imaging/who-was-Hakim.pdf|journal=Journal of Radiology and Medical Imaging|issn=2637-885X|via=MEDDOCS Open Access Publisher}}{{Cite web|last=Sussman, Ph.D|first=Marvin|date=2011-05-09|title=Dr. Salomon Hakim – a Giant in the Field of Hydrocephalus|url=https://www.hydroassoc.org/dr-salomon-hakim-a-giant-in-the-field-of-hydrocephalus/|access-date=2022-02-09|website=Hydrocephalus Association|language=en-US}}

In January 2021, the company acquired regenerative medicine firm, ACell, for $400M.{{Cite web|date=2020-12-16|title=Integra LifeSciences to acquire ACell|url=https://www.massdevice.com/integra-lifesciences-to-acquire-acell/|access-date=2022-01-12|website=MassDevice|language=en-US}}{{Cite web|date=January 21, 2021|title=Integra (IART) Acquires Acell, Focuses on Regenerative Space|url=https://www.nasdaq.com/articles/integra-iart-acquires-acell-focuses-on-regenerative-space-2021-01-21|website=Nasdaq}}

{{reflist}}

• {{Official website|https://www.integralife.com}}

{{Finance links

| name = Integra LifeSciences Holdings Corporation

| symbol = IART

| reuters = IART.O

| bloomberg = IART:US

| sec_cik = 917520

| yahoo = IART

| google = IART:NASDAQ

}}

Category:Companies based in Princeton, New Jersey

Category:Manufacturing companies of the United States

Category:Companies established in 1989

Category:Companies listed on the Nasdaq